Human Antibody-enabled Cardiovascular Personalized Theranosis

ABCardionostics Project

The project
"Through biotechnology and advanced imaging, we are working to identify high-risk patients earlier and offer personalized therapies."

Our Objectives

Develop novel 68Ga-labelled PET tracers and multi-marker PET/MR imaging protocols for improved atherosclerosis diagnosis.
Objective #1: Transformative Effect on Diagnosis
Develop bispecific antibodies (bsAbs), a next-generation targeted immunotherapy designed to promote plaque regression in atherosclerotic vascular disease (ASVD).
Objective #2: Transformative Effect on Therapy
1. Define plaque vulnerability by characterizing harmful and protective monocyte/macrophage (Mo/MP) subsets. 2. Identify molecular targets of human antibodies (HuAbs) and evaluate their potential as soluble biomarkers for ASVD.
Objective #3: Transformative Impact on ASVD Knowledge

Upcoming Events

ABCardionostics General Assembly

The ABCardionostics consortium will come together for its General Assembly[...]

view
CNRS Section 28 Congress in Reims

The CNRS Section 28 Congress in Reims features two half-days of high-level invited lectures [...]

view

8 partners from 3 European countries

consortium

NEWS

The ABCardionostics project has officially launched with a dynamic kick-off meeting on June 10-11 in Bordeaux, the home city of the project coordinator team. While the project officially started on April 1, 2024, this meeting marked the operational launch, bringing together all 8 consortium partners from France, Spain, and the Netherlands[…]

read